Avalon GloboCare Corp.

Avalon GloboCare to continue US-centric strategy with new proposed board composition ahead of Laboratory Services MSO acquisition

Avalon GloboCare to acquire majority interest in Laboratory Services MSO in 'transformative' deal worth $31M

Stock Market Today: What Happened & 3 Penny Stocks To Watch Now

Avalon GloboCare gets notice of allowance from US patent office for QTY fusion platform

Avalon GloboCare says its co-developed QTY code protein code technology featured in Chemical Reviews

Avalon GloboCare reveals new study using AI-powered protein design technology targeting glucose transporter against cancer

Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference

Avalon GloboCare to team up with Lu Daopei Hematology Institute to develop companion diagnostics for CAR-T cancer treatments

Avalon GloboCare files 16 patent applications related to cellular therapies as company moves towards clinical trials

Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform

Avalon GloboCare expands its cellular immuno-oncology program with addition of Chimeric Antigen Receptor-Natural Killer cell therapies

Avalon GloboCare well poised for growth this year; intended SenlangBio acquisition terminated

Avalon GloboCare advances its AI-enhanced protein design technology for cellular therapy development in collaboration with MIT

Avalon GloboCare successfully co-develops novel platform of S-layer coated emulsome technology for next-generation drug delivery and cellular immunotherapy

Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy

Avalon GloboCare announces co-development of in-silico system to expand its ability to design and produce novel cell membrane proteins

Avalon GloboCare's Advanced Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients

Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases

Avalon GloboCare Aims to Revolutionize Cell Therapy Market with a Faster, Safer CAR-T Treatment

AVALON GLOBOCARE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Avalon GloboCare Corp. - AVCO